Kidder Stephen W Has $7.44 Million Position in Novartis AG (NVS)
Kidder Stephen W cut its stake in shares of Novartis AG (NYSE:NVS) by 0.0% during the second quarter, Holdings Channel reports. The fund owned 89,148 shares of the company’s stock after selling 39 shares during the period. Novartis AG accounts for approximately 2.8% of Kidder Stephen W’s holdings, making the stock its 13th largest position. Kidder Stephen W’s holdings in Novartis AG were worth $7,440,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of the stock. First PREMIER Bank boosted its stake in shares of Novartis AG by 2.4% in the first quarter. First PREMIER Bank now owns 2,242 shares of the company’s stock valued at $166,000 after buying an additional 52 shares during the last quarter. Capstone Asset Management Co. boosted its stake in shares of Novartis AG by 7.6% in the first quarter. Capstone Asset Management Co. now owns 128,300 shares of the company’s stock valued at $9,529,000 after buying an additional 9,010 shares during the last quarter. TNB Financial bought a new stake in shares of Novartis AG during the first quarter valued at about $6,982,000. Hall Laurie J Trustee boosted its stake in shares of Novartis AG by 2.8% in the first quarter. Hall Laurie J Trustee now owns 16,663 shares of the company’s stock valued at $1,229,000 after buying an additional 450 shares during the last quarter. Finally, Prentiss Smith & Co. Inc. boosted its stake in shares of Novartis AG by 2.4% in the first quarter. Prentiss Smith & Co. Inc. now owns 136,441 shares of the company’s stock valued at $10,133,000 after buying an additional 3,239 shares during the last quarter. Institutional investors own 11.27% of the company’s stock.
Novartis AG (NYSE:NVS) opened at 83.35 on Friday. The stock has a market capitalization of $195.28 billion, a PE ratio of 30.43 and a beta of 0.73. The stock’s 50 day moving average price is $84.17 and its 200-day moving average price is $78.68. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90.
Novartis AG (NYSE:NVS) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 EPS for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.06. The business had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business’s revenue for the quarter was down 1.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.23 earnings per share. Analysts expect that Novartis AG will post $4.73 earnings per share for the current year.
Several analysts have issued reports on NVS shares. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a report on Tuesday, April 18th. Vetr cut Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 target price for the company. in a report on Tuesday, April 25th. Zacks Investment Research upgraded Novartis AG from a “strong sell” rating to a “hold” rating in a report on Monday, May 1st. UBS AG restated a “neutral” rating on shares of Novartis AG in a report on Wednesday, May 24th. Finally, Morgan Stanley restated a “sell” rating on shares of Novartis AG in a report on Tuesday, June 6th. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $83.56.
In other Novartis AG news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the stock in a transaction dated Wednesday, July 5th. The stock was acquired at an average price of $15.00 per share, with a total value of $4,000,005.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.01% of the stock is owned by insiders.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.